國立虎尾科技大學 |

Controversial statistical issues in clinical trials

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Controversial statistical issues in clinical trials/ Shein-Chung Chow.
作者:	Chow, Shein-Chung,
出版者:	Boca Raton :CRC Press, : c2011.,
面頁冊數:	1 online resource (xix, 591 p.) :ill. :
標題:	Drugs - Testing. -
電子資源:	http://www.crcnetbase.com/isbn/9781439849620
ISBN:	9781439849620 (electronic bk.)

Controversial statistical issues in clinical trials
Chow, Shein-Chung,1955-

Controversial statistical issues in clinical trials[electronic resource] /Shein-Chung Chow. - Boca Raton :CRC Press,c2011. - 1 online resource (xix, 591 p.) :ill. - Chapman & Hall/CRC biostatistics series. - Chapman & Hall/CRC biostatistics series..

Includes bibliographical references (p. 553-575) and index.

"Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "--

ISBN: 9781439849620 (electronic bk.)

LCCN: 2011024204Subjects--Topical Terms:

581825
Drugs
--Testing.

LC Class. No.: RM301.27 / .C475 2011

Dewey Class. No.: 615.5072/4

National Library of Medicine Call No.: QV 771

Controversial statistical issues in clinical trials
LDR:02335cam a2200277 a 4500 001 857696
005 20150206143227.0
006 m o d
007 cr |n|---|||||
008 170421s2011 flua ob 001 0 eng
010 $a 2011024204
020 $a 9781439849620 (electronic bk.)
020 $z 9781439849613 (hardback)
035 $a (DNLM)101562559
035 $a 16827822
040 $a DNLM/DLC $c DLC $d DLC
050 0 0 $a RM301.27 $b .C475 2011
060 1 0 $a QV 771
082 0 0 $a 615.5072/4 $2 23
100 1 $a Chow, Shein-Chung, $d 1955- $3 582020
245 1 0 $a Controversial statistical issues in clinical trials $h [electronic resource] / $c Shein-Chung Chow.
260 $a Boca Raton : $b CRC Press, $c c2011.
300 $a 1 online resource (xix, 591 p.) : $b ill.
490 1 $a Chapman & Hall/CRC biostatistics series
504 $a Includes bibliographical references (p. 553-575) and index.
520 $a "Preface In pharmaceutical/clinical development of a test drug or treatment, relevant clinical data are usually collected from subjects with the diseases under study in order to evaluate safety and efficacy of the test drug or treatment under investigation. To provide accurate and reliable assessment, well-controlled clinical trials under valid study design are necessarily conducted. Clinical trial process is a lengthy and costly process, which is necessary to ensure a fair and reliable assessment of the test treatment under investigation. Clinical trial process consists of protocol development, trial conduct, data collection, statistical analysis/interpretation, and reporting. In practice, controversial issues evitably occur regardless the compliance of good statistical practice (GSP) and good clinical practice (GCP). Controversial issues in clinical trials are referred to as debatable issues that are commonly encountered during the conduct of clinical trials. In practice, controversial issues could be raised from, but are not limited to, (1) compromises between theoretical and real/common practices, (2) miscommunication and/or misunderstanding in perception/interpretation among regulatory agencies, clinical scientists, and biostatisticians, and (3) disagreement, inconsistency, miscommunication/misunderstanding, and errors in clinical practice. "-- $c Provided by publisher.
588 $a Description based on print version record.
650 0 $a Drugs $x Testing. $3 581825
650 0 $a Drug development. $3 581824
650 0 $a Clinical trials. $3 581858
650 1 2 $a Clinical Trials as Topic. $3 780666
650 1 2 $a Drug Evaluation, Preclinical. $3 581967
650 2 2 $a Data Interpretation, Statistical. $3 563890
830 0 $a Chapman & Hall/CRC biostatistics series. $3 971089
856 4 0 $u http://www.crcnetbase.com/isbn/9781439849620